RxDoctor Payments Data

Sabiha Friedrich, MD

Internal Medicine · Albany, NYNPI 1811138845

Payments from drug & device makers

$9,833in general payments, 2019–2025

Across 520 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$976
  • AstraZeneca$717
  • Pfizer$521
  • Lilly USA, LLC$486
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,66598%
  • Education$1682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,833 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$34,521
Medicare patients
177
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$45,502
FarxigaDapagliflozin Propanediol39$38,437
EliquisApixaban24$27,274
MounjaroTirzepatide18$20,594
OzempicSemaglutide12$12,486
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,334
ValiumDiazepam12$6,405
SynthroidLevothyroxine Sodium43$4,028
Levothyroxine Sodium189$3,274
Fluvastatin ErFluvastatin Sodium11$2,452
Atorvastatin Calcium218$2,154
Losartan Potassium190$1,760
Omeprazole147$1,679
Metoprolol Succinate75$1,467
Wixela InhubFluticasone Propion/Salmeterol13$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$429$45,50228 claims
AstraZenecaFarxiga$717$38,43739 claims
PfizerEliquis$521$27,27424 claims
Lilly USA, LLCMounjaro$486$20,59418 claims
Novo NordiskOzempic$976$12,48612 claims
GSKTrelegy Ellipta$1,100$8,33413 claims
AbbVieSynthroid$1,909$4,02843 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$80$3,274189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →